
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Blood Cancer Diagnostics Market**

According to Intelli, the U.S. Blood Cancer Diagnostics Market size was valued at USD 4,031.4 Million in 2024 and is projected to reach USD 6,701.9 Million by 2032, growing at a CAGR of 6.98% from 2025 to 2032.



Blood cancer diagnostics stand at the forefront of a life‐and‐death battle, where every moment counts and precision can mean the difference between early intervention and disease escalation. From the subtle changes in white blood cell counts to the intricate genetic patterns uncovered through next-generation sequencing, modern diagnostic tools are transforming our ability to detect, analyze, and track leukemias, lymphomas, and myelomas with unmatched precision. As innovations from liquid biopsies that track tumor DNA in the bloodstream to digital pathology platforms powered by artificial intelligence, continue to accelerate, clinicians are better equipped than ever to tailor therapies, minimize toxicities, and improve patient outcomes. In this rapidly evolving landscape, the convergence of science, technology, and data is enabling healthcare professionals to better understand the genetic and molecular underpinnings of blood cancers, paving the way for targeted therapies that are tailored to the individual. As we push the limits of innovation, blood cancer diagnostics are not only a scientific achievement but also a fundamental shift in our approach to combating cancer.

**U.S. Blood Cancer Diagnostics Market Definition**

The U.S. Blood Cancer Diagnostics Market refers to the sector focused on the development, production, and distribution of diagnostic tools and technologies used to detect, diagnose, and monitor blood cancers, including leukemia, lymphoma, and myeloma. This market includes a diverse array of diagnostic approaches, such as blood tests, molecular assays, imaging methods, and biopsy techniques, all designed to detect genetic mutations, biomarkers, and cellular irregularities linked to blood cancers. In this evolving landscape, the U.S. blood cancer diagnostics market stands as both a symbol of scientific innovation and a reflection of our healthcare priorities where advancements in research, regulatory backing, and collaborative efforts come together to offer hope to thousands of patients annually.

A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Blood Cancer Diagnostics Market Overview**

The U.S. blood cancer diagnostics market is driven by several key factors, including the rising incidence of blood cancers like leukemia, lymphoma, and myeloma, which has created an increasing demand for effective diagnostic solutions. Technological advancements have played a transformative role in the field of blood cancer diagnostics, particularly through innovations like next-generation sequencing (NGS), liquid biopsy, and AI-powered imaging. NGS allows for the detailed analysis of genetic mutations and abnormalities in blood cancer cells, providing invaluable insights into the disease’s molecular underpinnings and enabling more precise diagnosis and treatment plans. Liquid biopsy, on the other hand, enables the detection of tumor DNA or circulating tumor cells in a patient's blood sample, offering a non-invasive alternative to traditional biopsy methods. In addition, enhanced government support and funding for cancer research, highlighted by the U.S. National Cancer Institute's investment in cancer diagnostics, have significantly accelerated the development of groundbreaking diagnostic technologies. Moreover, significant investments from leading companies in the diagnostics sector, combined with strategic collaborations within the industry, are fueling continuous innovation and enhancing access to advanced diagnostic solutions. Major players in the market are dedicating substantial resources to research and development, working to create more accurate, faster, and less invasive diagnostic tools.

**U.S. Blood Cancer Diagnostics Market Segmentation**

The U.S. Blood Cancer Diagnostics Market can be segmented based on product type, test type, and end-use. Each of these categories represents key areas within the market, catering to different diagnostic needs and patient care pathways.

**U.S. Blood Cancer Diagnostics Market, By Product**

* **Assay Kits and Reagents**
* **Instruments**

In the U.S. Blood Cancer Diagnostics Market, assay kits and reagents hold a significant market share, driven by their critical role in identifying biomarkers, genetic mutations, and other abnormalities associated with blood cancers. On the other hand, the instruments A close-up of hands holding a tablet and a pen

Description automatically generatedsegment, which includes cutting-edge diagnostic tools like hematology analyzers, flow cytometers, and molecular diagnostic devices, is also experiencing substantial growth. These instruments are pivotal in enabling fast and accurate results, particularly in complex diagnostic procedures such as next-generation sequencing and liquid biopsies.

**U.S. Blood Cancer Diagnostics Market, By Test Type**

* **Molecular Tests**
* **Blood Tests**
* **Imaging Tests and Biopsy**

In the U.S. Blood Cancer Diagnostics Market, molecular tests dominate the market share, fueled by their ability to provide highly detailed genetic and molecular insights that enable personalized treatment strategies for blood cancer patients. Blood tests, including complete blood counts (CBC) and specific biomarker tests, capture a significant share of the market, primarily due to their widespread use as initial screening methods and their cost-effectiveness and ease of administration. The imaging and biopsy segment, though smaller in size, remains essential for staging and assessing blood cancers, playing a pivotal role in diagnosis and treatment planning.

**U.S. Blood Cancer Diagnostics Market,** **By End-Use**

* **Hospitals and Clinics**
* **Diagnostic Laboratories**
* **Research Institutes**

In the U.S. Blood Cancer Diagnostics Market, hospitals and clinics represent the largest end-use segment, driven by their ability to offer comprehensive diagnostic services, including advanced testing and immediate patient care. The diagnostic laboratories segment closely follows, playing a crucial role in processing and analyzing blood samples for cancer detection. As the demand for high-quality diagnostic testing, particularly for molecular and genetic analysis, continues to rise, their contribution becomes even more significant. Additionally, research institutes are a key component of the market, driving innovation by developing new diagnostic technologies and treatment approaches for blood cancers. Though smaller in comparison, their role in driving innovation and improving diagnostic accuracy cannot be overstated, as they provide the foundation for future advancements.

A close-up of hands holding a tablet and a pen

Description automatically generated**Key Players**

The “U.S. Blood Cancer Diagnostics Market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Illumina, Siemens Healthineers, AbbVie, Agilent Technologies, Medtronic, F. Hoffmann-La Roche, Sysmex Corporation, Cleveland Diagnostics, Guardant Health, InVivoScribe, SkylineDx, Quest Diagnostics among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2025, the FDA approved the Echo Lumena, a device that automates in vitro blood testing for immunohematology. This approval marks a significant advancement in improving the speed and accuracy of blood testing procedures.
* In 2024, Researchers at Dana-Farber Cancer Institute have created a CRISPR-based tool to quickly detect gene fusions in Chronic Myelogenous Leukemia and Acute Promyelocytic Leukemia.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Blood Cancer Diagnostics Market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. Blood Cancer Diagnostics Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1. **INTRODUCTION OF** **U.S. BLOOD CANCER DIAGNOSTICS MARKET**
   1. Overview of the market
   2. Scope of report
   3. Assumptions
2. **EXECUTIVE SUMMARY**
3. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
4. **U.S. BLOOD CANCER DIAGNOSTICS MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. BLOOD CANCER DIAGNOSTICS MARKET, BY PRODUCT**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Assay Kits and Reagents

5.3 Instruments

**6 U.S. BLOOD CANCER DIAGNOSTICS MARKET, BY TEST TYPE**

6.1 Overview

6.2 Molecular Tests

6.3 Blood Tests

6.4 Imaging Tests and Biopsy

**7** **U.S. BLOOD CANCER DIAGNOSTICS MARKET, BY END-USE**

7.1 Overview

7.2 Hospitals and Clinics

7.3 Diagnostic Laboratories

7.4 Research Institutes

1. **U.S. BLOOD CANCER DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. **COMPANY PROFILES**

**9.1 Abbott Laboratories**

* + 1. Overview
    2. A close-up of hands holding a tablet and a pen

       Description automatically generatedFinancial Performance
    3. roduct Outlook
    4. Key developments
  1. **Roche Diagnostics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Thermo Fisher Scientific**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Illumina**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Siemens Healthineers**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **AbbVie**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  6. **Agilent Technologies**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Medtronic**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **F. Hoffmann-La Roche**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Sysmex Corporation**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Cleveland Diagnostics**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  4. **Guardant Health**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **InVivoScribe**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **SkylineDx**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Quest Diagnostics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. A close-up of hands holding a tablet and a pen

      Description automatically generated Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research